pegcetacoplan · Apellis Pharms · NDA 217171
Syfovre
Earliest generic entry, as listed
14 Dec 2038
Blocked by patent: US 12458695.
Listed patents · 15 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12458695 | product | 14 Dec 2038 |
| US 11903994 | use U-3827 | 22 Feb 2037 |
| US 11903994 | use U-3826 | 22 Feb 2037 |
| US 11903994 | use U-3828 | 22 Feb 2037 |
| US 12528836 | use U-4394 | 7 Oct 2036 |
| US 10035822 | substance | 15 Nov 2033 |
| US 10875893 | substance, use U-3540 | 15 Nov 2033 |
| US 11292815 | substance, product, use U-3540 | 15 Nov 2033 |
| US 10125171 | substance | 2 Aug 2033 |
| US 11661441 | substance, use U-3540 | 13 Jan 2033 |
| US 7888323 | substance | 4 Dec 2027 |
| US 7989589 | substance | 4 Dec 2027 |
| US 9169307 | substance, use U-3541 | 18 Nov 2027 |
| US 8168584 | use U-3542 | 7 Apr 2027 |
| US 8168584 | use U-3540 | 7 Apr 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217171 · 001 · RLD | solution, intravitreal | 15MG/0.1ML (15MG/0.1ML) | 14 Dec 2038 |
Expired or delisted (3)
- US 9056076 · use U-3540 · 25 Oct 2026
- NCE · 14 May 2026
- NP · 22 Feb 2026